Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. (ITCI) Revenue
Annual & quarterly revenue history · segment & region breakdown
ITCI · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsIntra-Cellular Therapies, Inc. trailing twelve-month (TTM) revenue is $0.68B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare ITCI revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Intra-Cellular Therapies, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Intra-Cellular Therapies, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Intra-Cellular Therapies, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ITCI revenue · 4 questionsITCI's trailing twelve-month (TTM) revenue is $0.68B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Intra-Cellular Therapies, Inc. SEC filings · GAAP · Intra-Cellular Therapies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026